Clinical Trial Detail

NCT ID NCT03225664
Title BATTLE-2 Program - A Biomarker-Integrated Targeted Therapy in Non-Small Cell Lung Cancer (NSCLC)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Pembrolizumab

Pembrolizumab + Trametinib

Age Groups: adult senior

No variant requirements are available.